# First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

> **NCT05586061** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 55 (actual)

## Conditions studied

- HER2-positive Gastric Cancer

## Interventions

- **DRUG:** Disitamab vedotin
- **DRUG:** Tislelizumab
- **DRUG:** S1

## Key facts

- **NCT ID:** NCT05586061
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-10
- **Primary completion:** 2024-12-29
- **Final completion:** 2025-12-31
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05586061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05586061, "First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05586061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*